SLC5A2 and type 2 diabetes mellitus: Moreover, the American Diabetes Association recently announced the rising importance of glucagon-like peptide-1 and sodium-glucose cotransporter-2 inhibitors to treat type 2 diabetes and its associated complications (American Diabetes Association, 2022); additional studies investigating the effects of these drugs are required.